GALNT7 and prostate carcinoma: To test if upregulation of GALNT7 can alter the cell surface O-glycosylation of prostate cancer cells, we created and validated stable prostate cancer cell line models with knockdown or up-regulation of GALNT7 (Supplementary Figure 5) and assessed the recognition by lectins.